Alzheon

Framingham, MA · Founded 2013 · Privately Held (backing)

Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. Alzheon is based in Framingham, MA and was founded in 2013. Its last reported valuation was $550 million in Apr 2022. It has raised $212 million across 9 recorded rounds; the latest was a $126 million later-stage round in Feb 2024.

Last reported valuation
$550.0M
Oct 2026
Priced at
—
Total raised
$212.2M
Last round
Later Stage VC
Feb 2024

Alzheon key facts

as of Oct 2026
  • Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders.
  • Alzheon is valued at approximately $550.0M as of Oct 2026 (last reported valuation).
  • It has raised $212.2M across 9 recorded rounds; the latest was Later Stage VC ($126.3M) in Feb 2024.
  • Notable investors include Ally Bridge Group, HCL Capital, Alerce Investment Management, Aptorum Group, Ron Sachs — 8 tracked in total.
  • Alzheon has filed 14 Form Ds with the SEC since 2013, most recently Feb 2025 ($126.3M sold to 76 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$550.0M

Alzheon's last reported valuation, Apr 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Alzheon with a free account
  • ·Watch Alzheon: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Alzheon funding rounds

9 rounds
Feb 2024Later Stage VC$126.3MSEC filing▮
Dec 2022Seed Round$1.7MSEC filing▮
Sep 2020Seed Round$2.4MSEC filing▮
Apr 2019Early Stage VC$6.2MSEC filing▮
May 2017Early Stage VC$19.8MSEC filing▮

Alzheon valuation

Alzheon's last reported valuation was $550 million in Apr 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Alzheon raised?

Alzheon has raised $212 million across 9 recorded rounds since 2013. The largest was a $7.3 million early-stage round in Dec 2014; the most recent was a $126 million later-stage round in Feb 2024.

Alzheon has filed 14 Form Ds with the SEC since 2013, most recently in Feb 2025 ($126 million sold to 76 investors).

Alzheon investors

8 investors are on record for Alzheon, including Ally Bridge Group, HCL Capital, Alerce Investment Management and Aptorum Group. The later-stage round in Feb 2024 drew 76 investors.

About Alzheon

Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. The company's platform specializes in the development of oral inhibitors of amyloid neurotoxicity by inhibiting protein misfolding and aggregation based on individual genetic and biological information, enabling the healthcare industry to treat neurological disorders efficiently.

Sector
Healthcare
HQ
Framingham, MA, United States
Founded
2013
Employees
32
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.